WO2009005798A8 - Antifungal formulation and method of preparation - Google Patents
Antifungal formulation and method of preparation Download PDFInfo
- Publication number
- WO2009005798A8 WO2009005798A8 PCT/US2008/008179 US2008008179W WO2009005798A8 WO 2009005798 A8 WO2009005798 A8 WO 2009005798A8 US 2008008179 W US2008008179 W US 2008008179W WO 2009005798 A8 WO2009005798 A8 WO 2009005798A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- acid sequence
- preparation
- fungal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 11
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 9
- 208000035143 Bacterial infection Diseases 0.000 abstract 4
- 206010017533 Fungal infection Diseases 0.000 abstract 4
- 208000031888 Mycoses Diseases 0.000 abstract 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 4
- 230000002538 fungal effect Effects 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 230000000813 microbial effect Effects 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 241000222122 Candida albicans Species 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical preparation for treating a microbial infection such as a fungal or bacterial infection in an individual comprises a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-1 13 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the buffer molarity of the pharmaceutical preparation is suitable to achieve greater than 99% killing of C. albicans in vitro. A pharmaceutical preparation for treating a microbial infection such as a fungal or bacterial infection in an individual comprises a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-113 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the pharmaceutical preparation has a buffer molarity of about 25 mM or less. A method for treating a microbial infection such as a fungal or bacterial infection in an individual comprises administering to the individual a therapeutically effective amount of a preparation comprising a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-113 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the buffer molarity of the preparation is suitable to achieve greater than 99% killing of C. albicans in vitro. A method for treating a microbial infection such as a fungal or bacterial infection in an individual comprises administering to the individual a therapeutically effective amount of a preparation comprising a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an ami
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95821607P | 2007-07-03 | 2007-07-03 | |
| US60/958,216 | 2007-07-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2009005798A2 WO2009005798A2 (en) | 2009-01-08 |
| WO2009005798A8 true WO2009005798A8 (en) | 2009-03-12 |
| WO2009005798A3 WO2009005798A3 (en) | 2009-08-13 |
Family
ID=40134809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/008179 WO2009005798A2 (en) | 2007-07-03 | 2008-07-01 | Antifungal formulation and method of preparation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009005798A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130310327A1 (en) | 2012-05-18 | 2013-11-21 | Rapid Pathogen Screening, Inc. | Histatin for Corneal Wound Healing and Ocular Surface Disease |
| US20170022256A1 (en) * | 2015-07-23 | 2017-01-26 | General Biologicals Corporation | Anti-fungal and anti-bacterial peptide and therapeutic method using same |
| US12195755B2 (en) | 2019-05-20 | 2025-01-14 | Brown University | Placental lipid bilayer for cell-free molecular interaction studies |
| US11273124B2 (en) | 2019-05-23 | 2022-03-15 | Brown University | Antifungal nanoparticles for targeted treatment of fungal infections |
| CN113975263B (en) * | 2021-10-20 | 2023-06-09 | 河南希百康健康产业有限公司 | Composition for inhibiting fungi and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631228A (en) * | 1991-11-01 | 1997-05-20 | Periodontix, Inc. | Anti-fungal and anti-bacterial histatin-based peptides |
-
2008
- 2008-07-01 WO PCT/US2008/008179 patent/WO2009005798A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009005798A2 (en) | 2009-01-08 |
| WO2009005798A3 (en) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8466102B2 (en) | Antimicrobial cationic peptides and formulations thereof | |
| KR101306643B1 (en) | Antimicrobial hexapeptides | |
| AU2006327973B2 (en) | Cyclic antimicrobial peptides | |
| US9181303B2 (en) | Treatment of bacterial infections with cyclic antimicrobial peptides | |
| JP2008509980A (en) | peptide | |
| WO2012142320A3 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| WO2002048183A3 (en) | Compositions of peptide crystals | |
| KR20130043625A (en) | Compounds and their use | |
| US20220370360A1 (en) | Compositions for treating viral infections and methods for same | |
| WO2009005798A8 (en) | Antifungal formulation and method of preparation | |
| KR101700603B1 (en) | An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition | |
| KR20160055343A (en) | An anti-microbial peptide Scolopendrasin-7 isolated from the Scolopendra subspinipes mutilans and its synthetic peptide | |
| KR20170052613A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
| AU2013226402B2 (en) | Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features | |
| NZ569946A (en) | Cyclic peptides comprising cationic amino acids and their use as antifungals | |
| WO2008070049A8 (en) | Peptide and treatment for hiv-1 infection | |
| JP2014512369A5 (en) | ||
| CN101415725B (en) | Peptide compound with biological activity, its preparation and its application | |
| AU2012203804A1 (en) | Cyclic antimicrobial peptides | |
| CN118987168A (en) | Multifunctional active peptide and application thereof | |
| KR20160014801A (en) | A New Lactoferricin-like peptide and its synthetic composition | |
| US20140194344A1 (en) | Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08779913 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08779913 Country of ref document: EP Kind code of ref document: A2 |